Clinical Trial Update: Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating neoadjuvant toripalimab plus nimotuzumab before radical therapy in Oral Squamous Cell Carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Oral Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN